生物技术公司CSL周二宣布裁员和分拆疫苗业务后，股价当日报收于每股225.50澳元，跌幅17%，创该股历史上的单日最大跌幅。随后，多位分析师下调了该股的目标价。

Barrenjoey医疗保健分析师Saul Hadassin将该股目标价从310澳元下调至258澳元，并将评级下调至“中性”。Wilsons Advisory分析师Shane Storey将目标股价从250澳元下调至227.50澳元。分析师们指出，该公司核心的血液制品业务表现令人失望，以及营收指引低于预期，是下调评级的主要原因。

周三早盘，CSL股价继续回落。10:06成交价为每股215.61澳元，跌幅4.39%。该股近一年的跌幅为30.05%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.